Clinical Web Archive

Sign in Subscribe

Cardiology

Phase 3 study results for oral PCSK9 inhibition with enlicitide.

Quick Take: Oral PCSK9 inhibition via enlicitide establishes a significant new therapeutic avenue for robust LDL-C reduction, potentially enhancing patient adherence. 💡 Clinical Impact * Mechanistic Why: Oral PCSK9 inhibition, as demonstrated by enlicitide, increases hepatic LDL receptor expression by preventing PCSK9-mediated degradation. This sustained increase in available receptors drives enhanced clearance

Percutaneous coronary intervention versus coronary artery bypass grafting for unprotected left main stenosis: 10-year final results from the randomised, open-label, non-inferiority NOBLE trial

Quick Take At the 10-year horizon, CABG remains the gold standard for unprotected left main (ULM) disease. While PCI and CABG show no significant difference in all-cause mortality or stroke, PCI is associated with a significantly higher MACCE rate, driven by spontaneous myocardial infarction and a persistent need for repeat

Glucagon-Like Peptide-1 Receptor Agonists and Major Adverse Cardiovascular Events in Patients With and Without Diabetes: A Meta-Analysis of Randomized-Controlled Trials

Quick Take GLP-1 receptor agonists (GLP-1 RAs) consistently reduce Major Adverse Cardiovascular Events (MACE). This benefit is now firmly established in Type 2 Diabetes (T2D) and is rapidly expanding into non-diabetic populations with obesity and established cardiovascular disease. 💡 Clinical Impact * The "Mechanistic Why": GLP-1 RAs offer pleiotropic benefits

The role of lipid lowering medications in the primary prevention of cardiovascular disease and mortality: a meta-analysis of randomized controlled trials.

Quick Take: This meta-analysis definitively solidifies the established benefit of lipid-lowering medications in preventing primary cardiovascular events and all-cause mortality. 💡 Clinical Impact * Patient Safety: Reaffirms the critical role of lipid-lowering therapy for appropriate primary prevention candidates to significantly reduce future cardiovascular morbidity and mortality. * Guideline Validation: Provides robust, high-quality evidence